




KDIGO Direct


KDIGO GUIDELINES



KDIGO 2020 Blood Pressure Management in Chronic Kidney Disease Guideline Approaching Publication

The KDIGO 2020 Clinical Practice Guideline on the Management of Blood Pressure (BP) in Chronic Kidney Disease (CKD) will publish online next Thursday, February 24, in *Kidney International*. The print edition will publish in *Supplements to Kidney International* with an Executive Summary in the journal's main pages. This guideline marks an update to the KDIGO 2012 BP Guideline. It includes new information on BP management recommendations for individuals with non-dialysis CKD, improving BP control for reducing cardiovascular disease risk in adults with CKD, and other important topics. The guideline was co-chaired by Alfred Cheung, MD, and Johannes Mann, MD.

KDIGO will share the guideline and related resources as soon as they are available. For more information, visit the [KDIGO Blood Pressure Management in CKD Guideline website](#).




Feedback Wanted: Scope of Work for KDIGO Autosomal Dominant Polycystic Kidney Disease Guideline Available for Public Review

KDIGO has announced that its next guideline will be on Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Scope of Work for the guideline is now available for public review. KDIGO encourages anyone interested or involved in the treatment of ADPKD to share their feedback. The deadline to submit comments has been extended until **March 1, 2021**.

The ADPKD Guideline Scope of Work is designed to briefly describe the rationale for the development of the guideline and to outline the topics that the guideline intends to address. Following a well-established KDIGO tradition, KDIGO invites clinicians to review and provide feedback on guideline Scope of Work. The goal is to ensure that the formal systematic review of literature includes global input, with a particular emphasis on suggestions that would most benefit patients and clinical practice.

The Scope of Work and feedback form can be found on the [ADPKD Guideline page on the KDIGO website](#).



KDIGO Glomerular Diseases Guideline to Publish Late Summer 2021

The KDIGO Clinical Practice Guideline on Glomerular Diseases is in the final stages of editing and will publish online in August 2021. The print edition will publish in September 2021. For more information and related resources, visit the [Glomerular Diseases Guideline page on the KDIGO website](#).

KDIGO CONTROVERSIES CONFERENCES



Genetics in Chronic Kidney Disease Controversies Conference

The virtual KDIGO Genetics in Chronic Kidney Disease (CKD) Controversies Conference, scheduled for March 2021, will examine several issues related to monogenic and complex kidney diseases, applying genetic findings in clinical medicine, and using genomics for defining and stratifying CKD. Anna Köttgen, MD (Germany), and Ali Gharavi, MD (United States), will co-chair this conference.

In the lead-up to the conference, KDIGO is conducting a Genetics in CKD webinar series. The first of this series, Episode 1: The Critical Role of Genetics in Kidney Disease – Not Just in Rare Kidney Diseases, features Conference Co-Chairs Anna Köttgen and Ali Gharavi. You can watch additional episodes on the [Genetics in CKD Controversies Conference page on the KDIGO website](#). Be sure to [register](#) for Episode 5 in this series: *Controversies, Barriers, and Practical Challenges to Genetic Testing in CKD*.



Home Dialysis Controversies Conference

The virtual KDIGO Controversies Conference on Home Dialysis, scheduled for May 2021, will be the third meeting in the KDIGO Dialysis Conference Series.

A select group of attendees will conduct a critical, in-depth review of specific and local factors that positively or negatively impact home dialysis, while considering criteria for candidacy, eligibility, and associated outcomes. Topics of particular consideration include the effect of increasing home dialysis

use on clinical and patient-reported outcomes, the financial implications of ESKD therapy costs (including patient and carer direct costs), and the impact of increasing home dialysis use on greater access to kidney replacement therapy. The conference will be co-chaired by Jeff Perl, MD (Canada), and Martin Wilkie, MD (UK).

While the Controversies Conference on Home Dialysis is limited to a select group of individuals, plenary session presentations and related conference resources will be available to the entire nephrology community on the [KDIGO Home Dialysis Controversies Conference page](#).

UPCOMING WEBINARS & EVENTS

Register for Episode 5 of the KDIGO Genetics in CKD Web Series: February 18, 2021

The next episode of KDIGO's Genetics in CKD Webinar Series: *Controversies, Barriers, and Practical Challenges to Genetic Testing in CKD*, will take place on Thursday, February 18 at 11:00 am EST / 5:00 pm CET. [Register today](#).

Join Professor Roser Torra, MD, and Professor Jan Halbritter, MD, as they explore the controversies, barriers, and practical challenges to genetic testing in chronic kidney disease. Learn more about the current landscape of genetic testing in CKD, explore the role of modifiers such as APOL1 and their implications, outline the ethical issues and social implications surrounding genetic testing, and discuss how best to incorporate patient views and patient-centered outcomes or experiences.

For a full overview of this 1.0 CME Credit webinar, visit bit.ly/Ep5CME.

KDIGO GENETICS IN CKD WEBINAR SERIES

EARN 1.0 CME CREDIT

EPISODE 5

CONTROVERSIES, BARRIERS, AND PRACTICAL CHALLENGES TO GENETIC TESTING IN CKD

THURSDAY, FEBRUARY 18 • 11:00AM EDT | 5:00PM CEST

PRESENTERS

Dr. Roser Torra
Fundació Puigvert
Barcelona, Spain

Dr. Jan Halbritter
Leipzig University
Leipzig, Germany

PROGRAM DESCRIPTION
Join Professor Roser Torra and Professor Jan Halbritter as they explore the controversies, barriers, and practical challenges to genetic testing in chronic kidney disease. This webinar will look at the current landscape of genetic testing in CKD, explore the role of modifiers such as APOL1 and their implications, outline the ethical issues and social implications surrounding genetic testing, and discuss how best to incorporate patient views and patient-centered outcomes or experiences.

TARGET AUDIENCE
The educational design of this activity addresses the needs of nephrologists and related specialists and allied health professionals involved in genetics and the treatment of patients with chronic kidney disease.

LEARNING OBJECTIVES

- Characterize genetic testing in general CKD and kidney disease of unknown etiology
- Define the role of modifiers and their implications
- Discuss the importance of informed consent and genetic counseling
- Describe how to communicate the implications of genetic testing with patients
- Outline the social and economic implications of genetic testing

RECENT WEBINARS & EVENTS

Translational Medicine Academy and KDIGO host e-SPACE CRM Conference

The Translational Medicine Academy, in collaboration with KDIGO, hosted e-SPACE CRM, the first global web conference on Cardiorenal Metabolic Syndrome from January 22-24, 2021. The event was designed to kick off a new generation of scientific conference, that is smart, patient-centered, accredited, collaborative, and educative (hence its name).



SAVE THE DATE
e-SPACE CRM

January 22-24, 2021
THE FIRST GLOBAL WEB-CONFERENCE ON
THE CARDIO-RENAL-METABOLIC SYNDROME

FREE REGISTRATION

Educational objectives

- Describe the complex pathophysiological interplay between cardiovascular disease, heart failure, diabetes and kidney disease.
- Recognize the need for a multidisciplinary team approach in the management of patients with patients with cardiac, renal and metabolic comorbidities.
- Analyze the results of current landmark clinical trials and their implications in clinical practice.
- Review novel pharmacological treatments and medical devices.
- Implement treatment algorithms.

10 Sessions
20 live panel discussion
40 talks by international experts

SPACE
Co-RE-NE-AL-ACADEMY
Global web-conference

KDIGO
Co-RE-NE-AL-ACADEMY
Global web-conference

• 3 days of digital experience
• 3 live shows
• LIVE & on demand
• CME credits

Thousands participated in the conference, attending a wide range of seminars that addressed a number of important topics such as arrhythmias in kidney disease and emerging treatment approaches for heart failure. The conference featured ten academic sessions shown twice across three time zones, 20 live academic panel discussions, over 80 speaks and chairs, and CME Accreditation from EBAC (European board of accreditation in cardiology, with conversion of credit points for AMA).

"We are delighted with the success of e-SPACE CRM," said KDIGO Co-Chair and conference co-chair and presenter, Wolfgang Winkelmayr MD. "It was a truly innovative program featuring an exceptional international faculty. I'm excited and impressed by the audience we were able to reach."

KDIGO and PlatformQ Host Expert-Led Glomerular Diseases Presentation



Edgar M. Lerma, MD, MChD, MPH, FASN, FIDP
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago College of
Medicine Alexander Group Medical Center
Oak Lawn, IL

Michelle M. O'Shaughnessy, MB, BCh, MCh,
FASN, FRCN
Consultant Nephrologist and Clinical Lecturer
Lecturer
Cork University Hospital
Cork, Ireland

Jai Radhakrishnan, MD, MEd,
FASN, FRCN
Professor of Medicine at Columbia University
Medical Center
Clinical Director, Nephrology, New York
Presbyterian Hospital, Columbia University
New York, NY

On Monday, February 8, KDIGO and PlatformQ launched a new, interactive, expert-led webinar: "Looking to the Future - Applying a Greater Understanding of Proteinuria Regulation to Improve Outcomes of Patients with FSGS and IgAN."

Edgar Lerma, MD (US), Michelle O'Shaughnessy, MD (Ireland), and Jai Radhakrishnan, MD (US) led a dynamic series of presentations that addressed the critical issues affecting patients with glomerular disease. The event highlighted the increasing prevalence of both focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) and how glomerular diseases often go undiagnosed until patients present with late-stage disease. The presentations endeavored to help improve recognition of early symptoms suggestive of glomerular disease and to learn the latest strategies to enhance diagnostic accuracy. Experts also discussed emerging targeted treatments and their ability to address the limitations of traditional treatments and to reduce proteinuria.

Recordings of these presentations will soon be available on the KDIGO website and available to the global nephrology community.



Support the Garabed Eknoyan, MD, Professorship in Nephrology at Baylor University

The Baylor College of Medicine has launched a campaign to honor KDIGO founder and leader, Gary Eknoyan, through the Garabed Eknoyan, MD, Professorship in Nephrology at Baylor University. KDIGO is helping in this effort to recognize Dr. Eknoyan and the significance of his contributions to KDIGO's mission and history.

KDIGO recognizes that a lasting result of his work is the very existence of clinical practice guidelines in nephrology. When Dr. Eknoyan looked into it in 1994, there were none. Now, KDIGO continues his vision of a global approach to improving outcomes for


patients.

We know that Dr. Eknoyan is a friend and colleague of many in the global nephrology community. A perfect way to honor him is by supporting this effort. For many years, Dr. Eknoyan has been generous to the cause of improving patient outcomes. He is still doing so by offering to match any contribution to the endowment of up to \$250,000.

Dr. Eknoyan's legacy is sustained through KDIGO and all the Baylor students he taught over the years. This professorship will continue the kind of teaching and mentoring for which he is known. Any support you can provide is greatly appreciated.

Donate to the Garabed Eknoyan, MD, Professorship in Nephrology:
www.givebmf.org/Eknoyan.

KDIGO IN THE NEWS - ARTICLES FROM OTHER PUBLICATIONS



CJASN: How I Treat: SGLT2 Inhibitors in Diabetic Kidney Disease

The latest from the CJASN "How I Treat" series on SGLT2 Inhibitors in Diabetic Kidney Disease by KDIGO Diabetes Guideline Work Group member, Dr. Sophia Zoungas, and Diabetes Guideline Co-Chair, Dr. Ian de Boer. [Read the full article.](#)

NEW CONTENT ON KDIGO YOUTUBE CHANNEL



Be sure to check out this month's new content on the KDIGO YouTube channel, including the "COVID-19 in Chronic Kidney Disease: Insights from Belgium" from the 2020 Shanghai HD Quality Control Annual Meeting.

[Subscribe](#) to the KDIGO YouTube channel and never miss another webinar or video.

About KDIGO

KDIGO is the global organization developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed charity incorporated in Belgium accountable to the public and the patients it serves.

[Learn More](#)



KDIGO | Avenue Louise 65, Suite 11, Brussels, 1050 Belgium

[Unsubscribe {recipient's email}](#)

[Update Profile](#) | [Customer Contact Data Notice](#)

Sent by kdigocommunications@kdigo.org